Enhancing Source Credibility in Tobacco Regulatory Communications

Center for Regulatory Research on Tobacco Communication, Project Credibility (PI: Adam O. Goldstein) Version 6: Protocol for Publication 8/21/2020 NCT03339206

Contents

| Administrative Information | |
|---|----------|
| Trial Registration | 4 |
| Funding | 4 |
| Roles and Responsibilities | 4 |
| Study Methods | |
| Population for this study | 5 |
| Experimental Conditions | 5 |
| Allocation and Blinding | 5 |
| Messages | 6 |
| Study Flow | 7 |
| Days 1-15: Morning Surveys | 8 |
| Message Order for Morning Surveys | 8 |
| Days 16 and 32: Post-test Surveys | 9 |
| Compensation Plan | 9 |
| Ethics and Trial Monitoring | |
| Data Safety | |
| Monitoring | |
| Declaration of Interests | |
| Dissemination Plan | |
| Statistical Analysis Plan | |
| Administration Information | |
| ClinicalTrials.gov ID | |
| SAP Revision History | |
| Introduction | |
| Background and Rationale | |
| Objectives | |
| Study Methods | |
| Trial Design | |
| Randomization | |
| Sample Size | |
| Sample Size Background: | |
| Assumptions for the power calculation: | 12 |
| Based on these assumptions: | |
| How does this compare to KyungSu's simulations? | |
| Recommendation: | |
| Framework | 14 |
| Statistical Interim Analyses and Stopping Guidance | 14 |
| Timing of Final Analysis | 14 |
| Timing of Outcome Assessments | 14 |
| Statistical Principles | 15 |
| Confidence Intervals and P Values | 15 |
| Level of statistical significance | 15 |
| Description and rationale for any adjustment for multiplicity and, if so detailing how the type 1 error | is to be |
| controlled | 15 |
| Confidence Intervals to be reported | |
| Adherence and Protocol Deviations | |
| Analysis Populations | 15 |
| Definition of analysis populations | |
| Trial Population | 16 |
| Screening Data | |

| Eligibility | 16 |
|--------------------------------------|----|
| Recruitment | |
| Withdrawal/follow-up | |
| Baseline participant characteristics | |
| Analysis | 19 |
| Outcome definitions | |
| Analysis Methods | |
| Post test measures | |
| Daily Questionnaire Measures | 21 |
| Harms | 21 |
| Statistical Software | 21 |
| References | 21 |
| Appendix A: Study Measures | |
| Appendix B: Trial Consent Form | |

Administrative Information

Trial Registration

Enhancing Source Credibility in Tobacco Regulatory Communications, NCT03339206, <u>https://clinicaltrials.gov/ct2/show/study/NCT03339206</u>

Registration Date: November 13, 2017

Funding

Research reported in this publication was supported by grant number P50 CA180907 from the National Cancer Institute and the FDA Center for Tobacco Products (CTP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Food and Drug Administration.

Roles and Responsibilities

| Name | Role | Affiliation | | | | |
|--------------------|------------------------|--|--|--|--|--|
| Adam O. Goldstein | Principal Investigator | Department of Family Medicine, University of North Carolina at Chapel Hill | | | | |
| | | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill | | | | |
| Kristen L. Jarman | Project Manager | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill | | | | |
| Sarah D. Kowitt | Doctoral Trainee | Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill | | | | |
| Bonnie E. Shook-Sa | Doctoral Trainee | Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill | | | | |
| Tara L. Queen | Statistician | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill | | | | |
| Kyung Su Kim | Statistician | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill | | | | |
| Leah M. Ranney | Co-Investigator | Department of Family Medicine, University of North Carolina at Chapel Hill | | | | |
| Paschal Sheeran | Co-Investigator | Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill | | | | |
| Seth M. Noar | Co-Investigator | Hussman School of Media and Journalism, University of North Carolina at Chapel Hill | | | | |

Study Methods

Following a pilot to test intervention feasibility, conduct a randomized controlled trial (RCT) of 800 young adult and adult smokers to test the hypothesis that optimally framed (high source credibility) FDA cigarette constituent messages will increase intentions to quit more than sub-optimally framed (no source attached) cigarette constituent messages or control messages (littering). Messages will be presented in a web-enabled format, derived from cigarette constituent (hereafter referred to as constituent) messages identified in Project 1 of our CRRTC, and framed based on the outcomes from Aim 2 of this project.

Population for this study

- 1. Age between 18 and 65
- 2. Current Smoker
- 3. Not currently enrolled in a smoking cessation program
- 4. Not currently using pharmacotherapy for smoking cessation
- 5. Work or home access to the Internet
- 6. Email account that they regularly use
- 7. Have not participated in a smoking study, other than phone survey, in last 3 months
- 8. Able to complete a survey on a computer
- 9. Able to complete a survey in English
- 10. Able to complete surveys delivered via email
- 11. Able to complete 3, 20-minute, surveys
- 12. Able to complete a 5-min survey each morning for 15 days
- 13. Lives in the US

Experimental Conditions

- Optimal Group: receive the risk and constituent messages with optimized source depiction and engagement formats.
- Suboptimal Group: receive the risk and constituent messages without source or engagement text.
- Control Group: receive littering messages


Allocation and Blinding

Participants will not be informed specifically about the possible interventions that they may be assigned to. Researchers will not be blinded to the condition that participants had been assigned to, however all outcome measures will be assessed via online survey.

At the end of the baseline survey, survey software will randomly assign participants to one of the three study arms. Participants will have an equal chance of being randomized to each study arm.

Messages

| Constituent Message | Words (Characters) | Littering Message | Words (Characters) |
|--|-----------------------|-----------------------------------|-----------------------|
| CIGARETTE SMOKE CONTAINS URANIUM THIS CAUSES LUNG TUMORS AND KIDNEY DAMAGE | 11 (76) | <section-header></section-header> | 11 (74) |
| CIGARETTE SMOKE CONTAINS ARSENIC THIS CAUSES HEART DAMAGE | 8 (59) | | 8 (55) |
| CIGARETTE SMOKE CONTAINS FORMALDEHYDE THIS CAUSES THROAT CANCER | 8 (65) | <section-header></section-header> | 8 (68) |




Study Flow

Pilot: Assess whether we can proceed and launch the full study when they have completed post-test 1, allow pilot participants to complete the full study (through post-test 2).

Full Study: Baseline survey, then a survey every morning for 15 days assessing previous day behavior and delivering a message. Follow up with post surveys at day 16 and 32.

Process:



Days 1-15: Morning Surveys

- There are 3 morning surveys, which align with each participant's condition. Participants will stay in their condition throughout the study. Depending on the day, participants will see a different message.
- The morning surveys will be sent out at 7am and will close at 10am. There will be a reminder email automatically sent at 8am if the participant has not yet completed the survey. The surveys will be sent according to each participant's time zone.
- At the end of the morning surveys, participants will see a message saying "You've completed [x] morning survey(s) so far. Keep up the good work!"
- When each survey is emailed out, participants will receive a note that says "If you have any problems, contact tobaccosurvey@unc.edu."

Message Order for Morning Surveys

- In week 1, participants see the following message order: 1-2-5-3-4 (sequence 1)
- In week 2, participants see the following message order: 2-3-1-4-5 (sequence 2)
- In week 3, participants see the following message order: 4-3-5-2-1 (sequence 6)

| Day | Message |
|--------|---------|
| Day 1 | 1 |
| Day 8 | 1 |
| Day 15 | 1 |
| Day 2 | 2 |
| Day 6 | 2 |
| Day 14 | 2 |
| Day 4 | 3 |
| Day 7 | 3 |
| Day 12 | 3 |
| Day 5 | 4 |
| Day 9 | 4 |
| Day 11 | 4 |
| Day 3 | 5 |
| Day 10 | 5 |
| Day 13 | 5 |

| Day | Message |
|--------|---------|
| Day 1 | 1 |
| Day 2 | 2 |
| Day 3 | 5 |
| Day 4 | 3 |
| Day 5 | 4 |
| Day 6 | 2 |
| Day 7 | 3 |
| Day 8 | 1 |
| Day 9 | 4 |
| Day 10 | 5 |
| Day 11 | 4 |
| Day 12 | 3 |
| Day 13 | 5 |
| Day 14 | 2 |
| Day 15 | 1 |

Conditions 1 and 2:

- Message 1 = Ammonia
- Message 2 = Arsenic
- Message 3 = Formaldehyde
- Message 4 = Lead
- Message 5 = Uranium

Condition 3:

- Message 1 = Bearded man with red trash bin
- Message 2 = Black man with yellow shirt
- Message 3 = White man with blue shirt
- Message 4 = Tan woman with orange hat and lots of cigarette butts in blue bin
- Message 5 = Asian woman with cigarette butts in her hand

Days 16 and 32: Post-test Surveys

- All participants will see the same post-test surveys.
- The post-test surveys will be sent out at 7pm and will close 24 hours later. There will be a reminder email automatically sent at 8pm if the participant has not yet completed the survey. The surveys will be sent according to each participant's time zone.

Compensation Plan

We will pay participants \$20 for the initial questionnaire and post-test 1 and post-test 2. We will also pay participants \$4 for each morning questionnaire.

Bonus system for daily questionnaire completion:

- Bronze: Total of \$10 bonus for at least 9 morning surveys. 1 entry into a drawing for additional money.
- Silver: Total of \$20 bonus for at least 12 morning surveys. 2 entries into a drawing for additional money.
- Gold: Total of \$30 for completing all 15 morning surveys. 3 entries into a drawing for additional money.

Participants may earn up to \$150 for the full study, and will be paid via check.

Drawing for additional money: Three \$200 checks will be administered for Bronze, Gold or Silver participants are entered into based on how many daily questionnaires they complete.

Participants will receive a message at the end of each morning survey regarding how many morning surveys they have completed. Participants will be paid after their participation in the study is completed.

Ethics and Trial Monitoring

This trial was approved by UNC's IRB under IRB #17-0610

All protocol changes will be communicated to the study team, and any change in participant interaction will be approved by UNC's IRB.

Data Safety

This study proposes research that has been determined to include Security Level 2 data security requirements. I agree to accept responsibility for managing these risks appropriately in consultation with departmental and/or campus security personnel. The Data Security Requirements addendum can be reviewed here: https://guides.lib.unc.edu/datasecurity/irbis

Monitoring

This trial presents no more than minimal risk to participants, so a data monitoring committee was not necessary. Similarly, the trial did not collect data on harms to participants, or assess interim data during the trial. Similarly, there is no need for ancillary or post-trail care.

Declaration of Interests

The study team declare that they have no competing interests.

Dissemination Plan

The study team plans to disseminate study findings via conference presentation and peer reviewed manuscripts in scientific journals. The study team will also share findings via ClinicalTrials.gov registration.

We will follow authorship guidelines depending on the journal to which manuscripts are submitted.

There are currently no plans to make a participant level dataset public.

Administration Information

ClinicalTrials.gov ID NCT03339206

SAP Revision History

| Version Number | Date | Summary of Changes |
|----------------|---------------|---|
| 1 | July 24, 2018 | SAP Created, agreed to by Adam O. Goldstein (Project PI), Tara L. Queen |
| | | (Statistical Analyst), KyungSu Kim (Statistical Analyst), and Kristen L. Jarman |
| | | (Study Coordinator, Document Originator) |

Introduction

Background and Rationale

The Family Smoking Prevention and Tobacco Control Act delegates the U.S. Food and Drug Administration (FDA) to communicate the risks of smoking to the public, among other tobacco regulatory responsibilities. Little research

exists about how FDA, as a regulatory agency, should develop and deliver these messages, and whether they should include their source information on the ads. This study will assess the impact of cigarette constituent messages

with and without FDA source and quit information in a randomized controlled trial. This study will assess the impact of cigarette constituent messages with and without FDA source and quit information in a randomized controlled trial.

Objectives

The investigators hypothesize that cigarette constituent messages will increase intention to quit compared to messages about littering cigarettes (the control). The investigators also hypothesize that constituent messages that include FDA source and quit information will increase intention to quit compared to messages without that information.

Study Methods

Trial Design Three group parallel trial.

The three conditions are:

- *Cigarette constituent message with FDA source and quit information*: Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
- *Cigarette constituent message without FDA source or quit information*: Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
- *Cigarette littering message (Control)*: Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by

investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.

Randomization

At the end of the baseline survey, survey software will randomly assign participants to one of the three study arms. Participants will have an equal chance of being randomized to each study arm.

Sample Size

Sample Size Background:

Our study is examining the difference in quit intention for participants that receive 1) Optimal constituent messages with quitline information, and self-efficacy information, or 2) Sub-optimal constituent messages or 3) Messages about littering cigarette butts.


No studies from the literature that we could find examined difference in quit intention or quitting behaviors by optimal text vs. sub-optimal warning text vs. control in a warning or smoking communication context.

In a meta-analysis by Noar et al. 2014 (Pictorial cigarette pack warnings: a meta-analysis of experimental studies) the effect size between pictorial vs. text only warnings on intention to quit smoking was d=0.54. Other outcomes ranged between effect size d=-0.03 (recall of warning text), and d=1.82 (intention not to start smoking).

Assumptions for the power calculation:

- The smallest effect size between our groups will be between the optimal and sub-optimal group. If we can see a difference between these groups, we will be able to see the larger effects that we expect between the other groups.
- We will be using a continuous measure of quit intention (or treating quit intention as a continuous variable, and collecting it as a categorical response).
- The effect size on quit intention is likely to be smaller for added self efficacy and quit line text than for added pictorial images.
- To be conservative, we will use a one time measure to calculate power, repeated measures would add power to this analysis (decrease necessary sample size).
- We will use the d statistic to see what group size would have to be enrolled, and compare two means (optimal and sub-optimal) with a t-test

Based on these assumptions:



The power calculation above is for a smaller effect size than the Noar 2016 paper, d=0.25. If we enroll 253 per group, we will have 80% power to detect a small difference between the optimal and sub-optimal group.

For our purposes, that would mean enrolling a total of at least 759 people.

How does this compare to KyungSu's simulations?

Based on Kyung Su's simulations, if we use 3 time points, and enroll around 750 people, we should be able to see an effect size of 0.35. This simulation is also very dependent on the assumptions that we started with.

Recommendation:

To be even more conservative, I would like to enroll at least 800 participants into our study to have enough power to see a d=0.25 difference between the optimal and sub-optimal groups.

Framework

Superiority – standard hypothesis testing framework

Statistical Interim Analyses and Stopping Guidance

NA, this study is no more than minimal risk to participants and does not pose a risk to their health, so we did not carry out any interim analyses or set guidelines for stopping the trial early.

Timing of Final Analysis

Final analysis will take place after all data collection for the RCT is complete.

| Time | Pre-Test | Morning | Post-Test 1 | Post-Test 2 |
|------------|---|--|--|---|
| Constructs | Sex, Sexuality Hispanic Origin, Race Address Education Age Health Household Size Income (above or below FPL) Trust in FDA and CDC Nicotine Dependence (FTND) Previous Quit Attempts Smoking Status Quit Intentions Littering Intention Self Efficacy Response Efficacy Positive and Negative Thoughts (Freq, Degree) Current OTP Use Knowledge of HE and Constituents Tripartite Risk Mental Health (K6) Study Information All Previous Day Behavior Qs | Previous day behaviors: Littering on the ground Littering from Car Forgoing Butting out Number of Cigarettes Cognitive Questions: Thinking about chemicals Thinking about risks Thinking about littering Thinking about quitting Message Negative Affect Message Credibility Perceived Effectiveness | Nicotine Dependence (FTND) Quit Attempts Smoking Status Quitline Awareness Quitline Use Quit Intentions Quitline Intention Littering Intention Littering Intention Self Efficacy Response Efficacy Positive and Negative Thoughts (Freq, Degree) Current OTP Use Knowledge of HE and Constituents Tripartite Risk Credibility of FDA Mental Health (K6) Action Expectancies Reactance Talking about messages All Previous Day Behavior Qs Quality Assurance Questions | Nicotine Dependence (FTND) Quit Attempts Smoking Status Quitline Use Quit Intentions Quitline Intention Littering Intention Self Efficacy Response Efficacy Positive and Negative Thoughts (Freq, Degree) Current OTP Use Knowledge of HE and Constituents Tripartite Risk Mental Health (K6) Action Expectancies All Previous Day Behavior Qs |

Timing of Outcome Assessments

Statistical Principles

Confidence Intervals and P Values Level of statistical significance α =0.05

Description and rationale for any adjustment for multiplicity and, if so detailing how the type 1 error is to be controlled NA

Confidence Intervals to be reported 95% CI

Adherence and Protocol Deviations

Definition of adherence to the intervention and how this is assessed including extent of exposure

Compliance with the protocol is assessed as follows:

- Completion of daily surveys, during which participants view intervention stimuli. % Compliance = number of daily surveys completed / 15 (number of surveys supposed to be completed)*100%
- Completion of post test surveys at post 1 and post 2

Description of how adherence to the intervention will be presented

- Adherence for the daily surveys will be presented with completion % as well as the mean number complete by treatment group
- Completion of post test surveys will be presented by % completing each by treatment group

Definition of protocol deviations for the trial

- Minor protocol deviation: change in eligibility (ex: turning 66) between screening and baseline
- Minor protocol deviation: completing the wrong sequence of message days due to survey signal error
- Major protocol deviation: No protocol deviations in this trial will impact the safety or physical or mental integrity
 of the participants in the trial. A slightly older participant, or a participant that receives a slightly different
 number of messages will both be included as covariates during analysis, so they will not impact the scientific
 validity of the trial. Therefore, we do not classify any protocol deviations as 'major'

Description of which protocol deviations will be summarized

 Protocol deviations will not be summarized overall, but data related to the deviations will be included in manuscripts. For example, we will not say X participants were older than 65, but will include mean age in a demographic table by treatment group. Similarly, we will not include how many people completed an extra 'day' of the protocol, but we will report the mean number of days participants completed by treatment group.

Analysis Populations

Definition of analysis populations

Outcomes assessed only at post test (including quit intentions) will be analyzed using multiple imputation such that everyone who was randomized will be included in the analysis, and those with missing outcome data will have their outcomes imputed.

For outcomes that were measured daily, all participants that completed at least one of the daily surveys will be included in the planned repeated measure models.

Secondary outcomes may be analyzed using complete case analysis, without imputation.

Trial Population

Screening Data

Screening data will be provided based on the CONSORT guidelines, and CONSORT flow chart will be included with publications.

Eligibility

Minimum Age: 18 Years

Maximum Age: 65 Years

Sex: All

Gender Based: No

Inclusion Criteria:


- Have smoked at least 100 cigarettes in his or her lifetime
- Currently smoke cigarettes every day or some days
- Work or home access to the internet
- Email account that is regularly used
- Lives in the US
- Comfortable taking a survey in English
- Able to complete a survey on a computer
- Able to complete surveys delivered via email
- Able to complete 3, 20 minute surveys during the study
- Able to complete surveys in the morning for 15 days

Exclusion Criteria:

- Currently using pharmacotherapy, a quitline, or a quit smoking program or support group for smoking cessation
- Participated in a research study about smoking cigarettes or using other tobacco products in the last 3 months

Recruitment

Recruitment data will be provided based on the CONSORT guidelines. The following CONSORT chart will be used as a template for reporting recruitment.



Withdrawal/follow-up

Level of withdrawal

- Data collection and the intervention occur using the same surveys, when a participant withdraws from data collection, they are withdrawing from follow up and the intervention.

Timing of withdrawal/lost to follow-up data

- Timing of withdrawal will be presented by treatment group, and categorized into each of the following timepoints:
 - o After baseline but before beginning intervention (before completing first daily survey)
 - During intervention (days 1-15)
 - During post-test follow up period (days 16-32)
 - After post-test follow up period (after day 32)

Reasons and details of how withdrawal/lost to follow-up data will be presented

- Numbers (with reasons) of loss to follow up and withdrawal over the course of the trial will be summarized by treatment group

Baseline participant characteristics *List of baseline characteristics to be summarized* See Draft Table 1 below.

Details of how baseline characteristics will be descriptively summarized Baseline characteristics will be descriptively summarized as show in Draft Table 1.S

Draft Table 1. Baseline Sample Characteristics

| Sample Characteristics | | Condition 1 (n=XXX) | | Condition 2 (n=XXX) | | Condition 3 (n=XXX) | | Total Sample (n=XXX) | |
|--|--------------|------------------------|--------------|------------------------|--------------|------------------------|--------------|-------------------------|--|
| | % or mean | 95% CI | % or mean | 95% CI | % or mean | 95% CI | % or mean | 95% Cl | |
| Gender | | | | | | | | | |
| Male | | | | | | | | | |
| Female | | | | | | | | | |
| Age, years | | | | | | | | | |
| Race | | | | | | | | | |
| White | | | | | | | | | |
| Black or African American | | | | | | | | | |
| Other Race | | | | | | | | | |
| Ethnicity | | | | | | | | | |
| Latino/Hispanic | | | | | | | | | |
| Non-Latino/Hispanic | | | | | | | | | |
| Education | | | | | | | | | |
| <high (hs)<="" school="" td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></high> | | | | | | | | | |
| G12 or GED, HS Diploma | | | | | | | | | |
| Some College | | | | | | | | | |

| Associate's degree | | | | |
|---|--|--|--|--|
| Bachelor's degree | | | | |
| Graduate or professional degree | | | | |
| Poverty Status | | | | |
| Below Poverty Line | | | | |
| Above Poverty Line | | | | |
| Sexual Orientation | | | | |
| Straight or heterosexual | | | | |
| Gay, lesbian, or bisexual | | | | |
| Current Cigarette Smoking | | | | |
| Current smoker | | | | |
| Nonsmoker | | | | |
| Fagerstrom Nicotine Dependence Score (FTND) | | | | |
| Trust in FDA | | | | |
| Number of Times Participants Viewed a Message During Follow Up | | | | |

To update Table 1 see 'Table 1 V1.xlsx' in Analysis Plan folder

Analysis

Outcome definitions

- Quit intentions [Time Frame: day 16] PRIMARY OUTCOME
 - 3 item measure with high reliability, average of the 3 items to create a score range 1-4 (Brewer et al., 2016, 2018; Klein, Zajac, & Monin, 2009)
 - We will compare the differences between pre and post
- Number of cigarettes smoked each day [Time Frame: Measured daily on days 1-15]
 - Continuous, Modified from FTND (Heatherton, Kozlowski, Frecker, & Fagerström, 1991; Storr, Reboussin, & Anthony, 2005)
- Number of cigarettes forgone each day [Time Frame: Measured daily on days 1-15]
 - Continuous, adapted from Brewer 2016 (Brewer et al., 2016)
 - \circ May be zero inflated, if yes, may choose to dichotomize to 0/1
- Number of cigarettes butted out each day [Time Frame: Measured daily on days 1-15]
 - Continuous, adapted from Brewer 2016 (Brewer et al., 2016)
 - May be zero inflated, if yes, may choose to dichotomize to 0/1
- Quit attempts during the study [Time Frame: Measured on days 16 and 32]
 - Adaptation from Fagan (Fagan et al., 2007)
 - \circ May be zero inflated, if yes, may choose to dichotomize to 0/1
- Awareness of quitline [Time Frame: Measured on day 16]
- Recall of quitline phone number [Time Frame: Measured on day 16]
- Use of the quitline during the study [Time Frame: Measured on days 16 and 32]
- Intention to use the quitline [Time Frame: Measured on days 16 and 32]
- Quit intentions [Time Frame: Measured on day 32]
 - 3 item measure with high reliability, average of the 3 items to create a score range 1-4 (Brewer et al., 2016, 2018; Klein et al., 2009)
 - \circ We will compare the differences between pre and post
- Self Efficacy [Time Frame: Measured on days 16 and 32]

- 1 item ("IARC HANDBOOKS OF CANCER PREVENTION," n.d.; Thrasher, Swayampakala, Borland, et al., 2016; Thrasher, Swayampakala, Cummings, et al., 2016)
- Response Efficacy [Time Frame: Measured on days 16 and 32]
 - 1 item (Thrasher, Swayampakala, Cummings, et al., 2016)

Analysis Methods

Analysis methods will depend on the time point that the outcome was measured. Post test measures will be analyzed differently than measures from the daily surveys, as outlined below.

Post test measures

What analysis method will be used and how treatment effects will be presented Linear regression for continuous outcomes, logistic for dichotomous.

Any adjustment for covariates

Covariates included for the imputation (in addition to treatment group):

- Dose of ads (# of times participants viewed a message)
- Gender (Male, Female, Other) (The GenIUSS Group, 2014)
- Age (continuous)
- Poverty Status (Above or Below Poverty Line) (Brewer et al., 2018; Department of Health and Human Services, 2017)
- Education (6 categories, same as phone survey)
- FTND Sum Using scoring from Heatherton et al. 1991 (Fagerstrom Test for Nicotine Dependence)(Fagerstrom, Heatherton, & Kozlowski, 1990; Heatherton et al., 1991)

Covariates included in the analysis model (in addition to treatment group):

- Dose of ads (# of times participants viewed a message)

Methods used for assumptions to be checked for statistical methods

For continuous outcomes, we assume the distribution of dependent variable given a predictor variable (intervention) is 1) independent 2) normality 3) constant variance (homogeneity of variance). We can check normality with Q-Q plot of the residual or perform Wilk-Shapiro test and use a scatter plot of residual on predictor variable (intervention) to check independence and constant variance.

Details of alternative methods to be used if distributional assumptions do not hold (eg normality, proportional hazards, etc)

If we have a violation for normality assumption, we can have two options: 1) transform our data so that the shape of our response variable become normally distributed or 2) choose the non-parametric method like Kruskal-Wallis which does not require the assumption of normality. The ANOVA can be considered a robust test against the normality assumption though. If the assumption of homogeneity of variances has been violated, we can use Welch or Brown and Forsythe test. Even though we alternatively perform a Kruskal-Wallis test, in most cases, Welch test is best. We don't expect to have dependency issues in our data.

Any planned sensitivity analyses for each outcome where applicable Sensitivity analyses may be carried out using a 'complete case analysis' framework

Any planned subgroup analyses for each outcome including how subgroups are defined None a priori

Missing Data

Multiple imputation will be used so that everyone who was randomized to an intervention will be included in the primary analysis

Additional Analyses None a priori

Daily Questionnaire Measures

What analysis method will be used and how treatment effects will be presented

Mixed models to account for repeated measures of the same participant.

Any adjustment for covariates

Covariates included in the analysis model (in addition to treatment group):

- Dose of ads (# of times participants viewed a message)

Methods used for assumptions to be checked for statistical methods

Linear mixed model is an extremely flexible for modeling continuous outcomes. It turns out that linear mixed models are robust to violations of some of their assumptions. The followings are the assumptions for linear mixed model: 1) Independent (The outcomes of different people are assumed to be statistically independent of each other.) Note: the outcomes within a person are correlated. 2) Normality (random effects are assumed to be normally distributed with mean zero and the residuals are normally distributed.)

Details of alternative methods to be used if distributional assumptions do not hold (eg normality, proportional hazards, etc)

Because mixed models are robust to violations of some of their assumptions, we do not anticipate needing to use an alternative method.

Any planned sensitivity analyses for each outcome where applicable None a priori

Any planned subgroup analyses for each outcome including how subgroups are defined None a priori

Missing Data

Mixed models are appropriate to use and robust to missing data, so we will be able to include everyone who completed at least 1 daily questionnaire.

Additional Analyses None a priori

Harms

Adverse events were not expected in this trial due to the minimal risks to participants, and no threat to participant health, so this section is not applicable.

Statistical Software

Statistical analyses will be conducted in SAS 9.4 (Cary, NC)

References

Final Dataset: rct_combined_07232018 [location removed]

Data Cleaning Syntax: 01_Create_Analytic_Files.sas [location removed]

Study Protocol: RCT_Protocol_V5 [location removed]

Analysis plan compiled according to "Guidelines for the Content of Statistical Analysis Plans in Clinical Trials" (Gamble et al., 2017)

- Brewer, N. T., Hall, M. G., Noar, S. M., Parada, H., Stein-Seroussi, A., Bach, L. E., ... Ribisl, K. M. (2016). Effect of Pictorial Cigarette Pack Warnings on Changes in Smoking Behavior: A Randomized Clinical Trial. JAMA Internal Medicine, 176(7), 905–912. https://doi.org/10.1001/jamainternmed.2016.2621
- Brewer, N. T., Jeong, M., Mendel, J. R., Hall, M. G., Zhang, D., Parada, H., ... Ribisl, K. M. (2018). Cigarette pack messages about toxic chemicals: a randomised clinical trial. *Tobacco Control*, tobaccocontrol-2017-054112. https://doi.org/10.1136/tobaccocontrol-2017-054112
- Department of Health and Human Services. (2017). 2017 Annual Update of the HHS Poverty Guidelines. Federal Register (Vol. 82). Retrieved from https://www.gpo.gov/fdsys/pkg/FR-2017-01-31/pdf/2017-02076.pdf
- Fagan, P., Augustson, E., Backinger, C. L., O'Connell, M. E., Vollinger, R. E., Kaufman, A., ... Gibson, J. T. (2007). Quit attempts and intention to quit cigarette smoking among young adults in the United States. *American Journal of Public Health*, 97(8), 1412–1420. https://doi.org/10.2105/AJPH.2006.103697
- Fagerstrom, K. O., Heatherton, T. F., & Kozlowski, L. T. (1990). Nicotine addiction and its assessment. *Ear, Nose, & Throat Journal, 69*(11), 763–765. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2276350
- Gamble, C., Krishan, A., Stocken, D., Lewis, S., Juszczak, E., Doré, C., ... Loder, E. (2017). Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. *JAMA*, *318*(23), 2337. https://doi.org/10.1001/jama.2017.18556
- Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine
 Dependence: a revision of the Fagerström Tolerance Questionnaire. *British Journal of Addiction*, *86*(9), 1119–1127.
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1932883
- IARC HANDBOOKS OF CANCER PREVENTION. (n.d.). International Agency for Research on Cancer World Health Organization, 12. Retrieved from http://www.iarc.fr/en/publications/pdfsonline/prev/handbook12/Tobacco_vol12_cover.pdf
- Klein, W. M. P., Zajac, L. E., & Monin, M. M. (2009). Worry as a Moderator of the Association Between Risk Perceptions and Quitting Intentions in Young Adult and Adult Smokers. *Annals of Behavioral Medicine*, 38(3), 256–261. https://doi.org/10.1007/s12160-009-9143-2
- Storr, C. L., Reboussin, B. A., & Anthony, J. C. (2005). The Fagerström test for nicotine dependence: A comparison of standard scoring and latent class analysis approaches. *Drug and Alcohol Dependence*, *80*(2), 241–250. https://doi.org/10.1016/j.drugalcdep.2004.04.021
- The GenIUSS Group. (2014). Best Practices for Asking Questions to Idenfity Transgender and Other Gender Minority Respondents on Population-Based Surveys. Retrieved from https://williamsinstitute.law.ucla.edu/wpcontent/uploads/geniuss-report-sep-2014.pdf
- Thrasher, J. F., Swayampakala, K., Borland, R., Nagelhout, G., Yong, H.-H., Hammond, D., ... Hardin, J. (2016). Influences of Self-Efficacy, Response Efficacy, and Reactance on Responses to Cigarette Health Warnings: A Longitudinal Study of Adult Smokers in Australia and Canada. *Health Communication*, *31*(12), 1517–1526. https://doi.org/10.1080/10410236.2015.1089456
- Thrasher, J. F., Swayampakala, K., Cummings, K. M., Hammond, D., Anshari, D., Krugman, D. M., & Hardin, J. W. (2016). Cigarette package inserts can promote efficacy beliefs and sustained smoking cessation attempts: A longitudinal assessment of an innovative policy in Canada. *Preventive Medicine*, *88*, 59–65. https://doi.org/10.1016/j.ypmed.2016.03.006

Appendix A: Study Measures

Constructs by Timeframe

| Time | Pre-Test | Morning | Post-Test 1 | Post-Test 2 |
|------------|---|--|---|---|
| Constructs | Sex, Sexuality Hispanic Origin, Race Address Education Age Health Household Size Income (above or below FPL) Trust in FDA and CDC Nicotine Dependence (FTND) Previous Quit Attempts Smoking Status Quit Intentions Littering Intention Self Efficacy Response Efficacy Positive and Negative Thoughts (Freq, Degree) Current OTP Use Knowledge of HE and Constituents Tripartite RiskMental Health (K6) Study Information All Previous Day Behavior Qs | Previous day behaviors: Littering on the ground Littering from Car Forgoing Butting out Number of Cigarettes Cognitive Questions: Thinking about chemicals Thinking about risks Thinking about littering Thinking about quitting Message Negative Affect Message Credibility Perceived Effectiveness | Nicotine Dependence (FTND) Quit Attempts Smoking Status Quitline Awareness Quitline Use Quit Intentions Quitline Intention Littering Intention Self Efficacy Response Efficacy Positive and Negative Thoughts (Freq, Degree) Current OTP Use Knowledge of HE and Constituents Tripartite Risk Credibility of FDA Mental Health (K6) Action Expectancies Reactance Talking about messages All Previous Day Behavior Qs Quality Assurance Questions | Nicotine Dependence (FTND) Quit Attempts Smoking Status Quitline Use Quit Intentions Quitline Intention Littering Intention Self Efficacy Response Efficacy Positive and Negative Thoughts (Freq, Degree) Current OTP Use Knowledge of HE and Constituents Tripartite Risk Mental Health (K6) Action Expectancies All Previous Day Behavior Qs |

| Day 0 - Pre-Test | • | Day 1 •Morning: View message and 5 min survey •Evening: 5 min survey | • | Day 2-5 (Repeat Day 1 with new messages) •Morning: View message and 5 min survey •Evening: 5 min survey | | Day 6-16 (Repeat days 1-5 2x) • Morning: View message and 5 min survey • Evening: 5 min survey | | Day 16 - Post-Test 1 | | Day 32 - Post-Test 2 |
|------------------|---|---|---|--|--|--|--|-------------------------|--|-------------------------|
|------------------|---|---|---|--|--|--|--|-------------------------|--|-------------------------|

Pre, Post 1, Post 2

| Construct (Source) | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|-----------------------|---|-----------------|------------------|-----------------|-----------------|
| Instruction | Please read the consent form on the next page to learn more about our research study and what we are asking participants to do. | | Instruction | | |
| Post 1 Instruction | You have now finished the part of the study with daily surveys. | | | Post1_Inst | |
| | This slightly longer survey should take you less than 20 minutes to complete. If you complete the survey, you will be paid an additional \$20 in your incentive check. | | | | |
| Post 2 Instruction | This will be the last survey for this study. Thank you for your participation! | | | | Post2_Inst |
| | This survey should take you less than 20 minutes to complete. If you complete the survey, you will be paid an additional \$20 in your incentive check. | | | | |
| PAGE BREAK | | | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|----------------------------|---|-----------------------------|------------------|-----------------|-----------------|
| (Source) | | | | | |
| Consent | [Include current consent form with | | ConsentForm1, | | |
| Form | agreement to participate] | | ConsentForm_Gra | | |
| | | | phicConsentForm | | |
| | | | 2, ConsentForm3 | | |
| PAGE BREAK | | | | | |
| Sex1 ¹ | What sex were you assigned at birth, on | 1 = Male | Sex1 | | |
| | your original birth certificate? Was it | 2 = Female | | | |
| 1 | | | | | |
| Sex2 ¹ | Do you describe yourself as | 1= Male | Sex2, Sex2_Text | | |
| | | 2= Female | | | |
| | | 3= Transgender | | | |
| | | 4= Other | | | |
| | | (specify) | | | |
| Sexual | Do you consider yourself to be | 1= Straight or heterosexual | Sexuality, | | |
| Orientation ^{2,3} | | 2= Gay or lesbian | Sexuality_Text | | |
| | | 3= Bisexual | | | |
| | | 4= OTHER | | | |
| | | (specify) | | | |
| Page Break | | | · | | |
| Hispanic | Are you of Hispanic, Latino, or Spanish | 0= No | Hisp | | |
| Origin ³ | origin? | 1 = Yes | | | |
| Race ³ | Which one of these groups would you say | 1=White | Race | | |
| | best represents your race? | 2=Black or African American | | | |
| | | 3=American Indian or Alaska | | | |
| | | Native | | | |
| | | 4=Asian | | | |
| | | 5=Pacific Islander | | | |
| | | 6=Other | | | |
| Page Break | | | | | |

| Construct (Source) | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|-----------------------|--|--|------------------|-----------------|-----------------|
| Instruction to | Please provide your mailing address below. | | Instr3 | | |
| provide | This is where we will send your incentive | | | | |
| name and | check at the end of the study. | | | | |
| | check at the end of the study. | | | | |
| address | | | | | |
| First Name | First Name | Free Response | FirstName | | |
| Last Name | Last Name | Free Response | LastName | | |
| Address Line | Street Number, Street Name | Free Response (Validity Check) | Addr1 | | |
| 1 | | | | | |
| Address Line | Apartment Number, Optional Address Line | Free Response (Validity Check, | Addr2 | | |
| 2 | 2 | Optional Response) | | | |
| City | City | Free Response (Validity Check) | City | | |
| Zip | Zip Code | Free Response | Zip | | |
| State | State | Dropdown list | State_0 | | |
| State | State | 1= ALABAMA | State_0 | | |
| | | 2= ALASKA | | | |
| | | 3= ARIZONA | | | |
| | | 4= ARKANSAS | | | |
| | | 5= CALIFORNIA | | | |
| | | 6= COLORADO | | | |
| | | 7= CONNECTICUT 8= DELAWARE | | | |
| | | 9= DILAWARE 9= DISTRICT OF COLUMBIA | | | |
| | | 10= FLORIDA | | | |
| | | 11= GEORGIA | | | |
| | | 12= HAWAII | | | |
| | | 13= IDAHO | | | |
| | | 14= ILLINOIS | | | |
| | | 15= INDIANA | | | |
| | | 16= IOWA | | | |
| | | 17= KANSAS | | | |
| | | 18= KENTUCKY | | | |
| | | | | | |
| | | 20= MAINE 21= MARYLAND | | | |
| | | 22= MASSACHUSETTS | | | |
| | | 23= MICHIGAN | | | |
| | | 24= MINNESOTA | | | |
| | | 25= MISSISSIPPI | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|------------|----------------------------|---|------------------|-----------------|-----------------|
| (Source) | | | | | |
| | | 26= MISSOURI 27= MONTANA 28= NEBRASKA 29= NEVADA 30= NEW HAMPSHIRE 31= NEW JERSEY 32= NEW MEXICO 33= NEW YORK 34= NORTH CAROLINA 35= NORTH DAKOTA 36= OHIO 37= OKLAHOMA 38= OREGON 39= PENNSYLVANIA (40=Puerto Rico* Option not displayed, included to align with screener for phone survey participants) 41= RHODE ISLAND 42= SOUTH CAROLINA 43= SOUTH DAKOTA 44= TENNESSEE 45= TEXAS 46= UTAH 47= VERMONT 48= VIRGINIA 49= WASHINGTON 50= WEST VIRGINIA 51= WISCONSIN 52= WYOMING | | | |
| PAGE BREAK | | -5=Eastern Standard Time (Ex: New York) | | | |
| Time Zone | What time zone are you in? | -6=Central Standard Time (Ex: Chicago) -7=Mountain Standard Time (Ex: Salt Lake City) -8=Pacific Standard Time (Ex: Los Angeles) -9=Alaska Standard Time (Ex: Anchorage) -10=Hawaii-Aleutian Standard Time (Ex: Honolulu) | TimeZone | | |
| PAGE BREAK | | | | | |
| Cell Phone | Do you have a cell phone? | 1=Yes | Cell_YN | | |
| Number | | 0=No | | | |
| PAGE BREAK | | | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|------------------------|--|--------------------------------|------------------|-----------------|-----------------|
| (Source) | | | | | |
| Cell Phone | Cell Phone Number | Free Response (Validity Check) | Phone_Number | | |
| Number | | | | | |
| Page Break | - | | | | |
| Education ³ | What is the highest degree or level of | [0= NO SCHOOLING COMPLETED | Edu | | |
| | school you have completed? | 1= NURSERY SCHOOL TO 4TH | | | |
| | | GRADE | | | |
| | | 2= 5TH OR 6TH GRADE | | | |
| | | 3= 7TH OR 8TH GRADE | | | |
| | | 4= 9TH GRADE | | | |
| | | 5= 10TH GRADE | | | |
| | | 6= 11TH GRADE | | | |
| | | 7= 12TH GRADE - NO DIPLOMA | | | |
| | | 8= HIGH SCHOOL GRADUATE - | | | |
| | | high school diploma or the | | | |
| | | equivalent (for example: GED) | | | |
| | | 9= SOME COLLEGE CREDIT, BUT | | | |
| | | LESS THAN 1 YEAR | | | |
| | | 10= 1 OR MORE YEARS OF | | | |
| | | COLLEGE, NO DEGREE | | | |
| | | 11= ASSOCIATE'S DEGREE (FOR | | | |
| | | EXAMPLE: AA, AS) | | | |
| | | 12= BACHELOR'S DEGREE (FOR | | | |
| | | EXAMPLE: BA, AB, BS) | | | |
| | | 13= MASTER'S DEGREE (FOR | | | |
| | | EXAMPLE: MA, MS, MEng, MEd, | | | |
| | | MSW, MBA) | | | |
| | | 14= PROFESSIONAL DEGREE (FOR | | | |
| | | EXAMPLE: MD, DDS, DVM, LLB, | | | |
| | | JD) | | | |
| | | 15= DOCTORATE DEGREE (FOR | | | |
| | | EXAMPLE: PhD, EdD)] | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|------------------------|---|--|------------------|-----------------|-----------------|
| (Source) | | | | | |
| Page Break | | | 1 | T | |
| Age | How old are you? | Free response (Must be 3 or | Age | | |
| | | fewer numbers, between 18-120) | | | |
| General | Would you say that in general your health | 5= Excellent | Health | | |
| Health ³ | is: | 4= Very Good | | | |
| | | 3= Good | | | |
| | | 2= Fair | | | |
| | | 1= Poor | | | |
| Household ⁴ | How many people are in your household, | # of people [restricted to 1-10] | Household | | |
| | including you? | | | | |
| | | | | | |
| Income ^{4,5} | [Ask only if Household = 1, else skip to | 1=Less than \$12,060 | Income_1 | | |
| | FTND 1] | 2=Between \$12,060 and \$18,089 | | | |
| | | 3=Between \$18,090 and \$24,119 | | | |
| | Which of the following categories best | 4=Between \$24,120 and \$30,149 | | | |
| | describes your total household income in | 5=Between \$30,150 and \$36,179 | | | |
| | the last 12 months? | 6=\$36,180 or more | | | |
| | [Ask only if Household = 2, else skip to | 1=Less than \$16,240 | Income_2 | | |
| | FTND 1] | 2=Between \$16,240 and \$24,359 | | | |
| | | 3=Between \$24,360 and \$32,479 | | | |
| | Which of the following categories best | 4=Between \$32,480 and \$40,599 5=Between \$40,600 and \$48,719 | | | |
| | describes your total household income in | 6=\$48,720 or more | | | |
| | the last 12 months? | | | | |
| | [Ask only if Household = 3, else skip to FTND 1] | 1=Less than \$20,420 2=Between \$20,420 and \$30,629 | Income_3 | | |
| | | 3=Between \$30,630 and \$40,839 | | | |
| | Which of the following categories best | 4=Between \$40,840 and \$51,049 | | | |
| | describes your total household income in | 5= Between \$51,050 and \$61,259 | | | |
| | the last 12 months? | 6=\$61,260 or more | | | |
| | [Ask only if Household = 4, else skip to | 1=Less than \$24,600 | Income_4 | | |
| | FTND 1] | 2=Between \$24,600 and \$36,899 | | | |
| | | 3=Between \$36,900 and \$49,199 | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|-----------|---|--|------------------|-----------------|-----------------|
| (Source) | | | | | |
| | Which of the following categories best | 4=Between \$49,200 and \$61,499 | | | |
| | describes your total household income in | 5=Between \$61,500 and \$73,799 | | | |
| | the last 12 months? | 6=\$73,800 or more | | | |
| | [Ask only if Household = 5, else skip to | 1=Less than \$28,780 | Income_5 | | |
| | FTND 1] | 2=Between \$28,780 and \$43,169 | | | |
| | Which of the following categories best | 3=Between \$43,170 and \$57,559 4=Between \$57,560 and \$71,949 | | | |
| | describes your total household income in | 5=Between \$71,950 and \$86,339 | | | |
| | the last 12 months? | 6=\$86,430 or more | | | |
| | [Ask only if Household = 6, else skip to | 1=Less than \$32,960 | Income_6 | | |
| | FTND 1] | 2=Between \$32,960 and \$49,439 | income_6 | | |
| | | 3=Between \$49,440 and \$65,919 | | | |
| | Which of the following categories best | 4=Between \$65,920 and \$82,399 | | | |
| | describes your total household income in | 5=Between \$82,400 and \$98,879 | | | |
| | the last 12 months? | 6=\$98,880 or more | | | |
| | [Ask only if Household = 7, else skip to | 1=Less than\$37,140 | Income_7 | | |
| | FTND 1] | 2=Between \$37,140 and \$55,709 | | | |
| | | 3=Between \$55,710 and \$74,279 | | | |
| | Which of the following categories best | 4=Between \$74,280 and \$92,849 | | | |
| | describes your total household income in | 5= Between \$92,850 and | | | |
| | the last 12 months? | \$111,419 6 \$111 420 on more | | | |
| | | 6=\$111,420 or more | | | |
| | [Ask only if Household = 8, else skip to FTND 1] | 1=Less than \$41,320 2=Between \$41,320 and \$61,979 | Income_8 | | |
| | | 3=Between \$61,980 and \$82,639 | | | |
| | Which of the following categories best | 4=Between \$82,640 and | | | |
| | describes your total household income in | \$103,299 | | | |
| | the last 12 months? | 5=Between \$103,300 and | | | |
| | | \$123,959 | | | |
| | | 6=\$123,960 or more | | | |
| | [Ask only if Household = 9, else skip to | 1=Less than \$45,500 | Income_9 | | |
| | FTND 1] | 2=Between \$45,500 and \$68,249 | | | |
| | | 3=Between \$68,250 and \$90,999 | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|-------------------------|---|---------------------------------|------------------|-----------------|-----------------|
| (Source) | | | | | |
| | Which of the following categories best | 4=Between \$91,000 and | | | |
| | describes your total household income in | \$113,749 | | | |
| | the last 12 months? | 5=Between \$113,750 and | | | |
| | | \$136,549 | | | |
| | | 6=\$136,500 or more | | | |
| | [Ask only if Household = 10, else skip to | 1=Less than \$49,680 | Income_10 | | |
| | FTND 1] | 2=Between \$49,680 and \$74,519 | | | |
| | | 3=Between \$74,520 and \$99,359 | | | |
| | Which of the following categories best | 4=Between \$99,360 and | | | |
| | describes your total household income in | \$124,199 | | | |
| | the last 12 months? | 5=Between \$124,200 and | | | |
| | | \$149,039 | | | |
| | | 6=\$149,040 or more | | | |
| Page Break | | | | | |
| Trust in | How much trust do you have in the Federal | 5= A great deal | TrustGov_Pre | | |
| Gov ^{3,6} | government? | 4= A fair amount | | | |
| | | 2= Not very much | | | |
| | | 1= None at all, or | | | |
| | | 3= No opinion | | | |
| Trust in | In your opinion, does the Food and Drug | 5 = Definitely yes | FDA_Pre | | |
| FDA ^{3,6} | Administration, or FDA, give trustworthy | 4 = Probably yes | | | |
| | information to the public? | 3 = Neither yes or no | | | |
| | | 2 = Probably no | | | |
| | | 1 = Definitely no | | | |
| Trust in | In your opinion, does the Centers for | 5 = Definitely yes | CDC_Pre | | |
| CDC ^{3,6} | Disease Control and Prevention, or CDC, | 4 = Probably yes | | | |
| | give trustworthy information to the public? | 3 = Neither yes or no | | | |
| | | 2 = Probably no | | | |
| | | 1 = Definitely no | | | |
| Page Break | | · | - | • | |
| Nicotine | How soon after you wake up do you smoke | 3 = Within 5 minutes | FTND1_Pre | FTND1_Post1 | FTND1_Post2 |
| Dependence ⁷ | your first cigarette? | 2 = 6 – 30 minutes | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|-------------------------|---|----------------------------------|------------------|-----------------|-----------------|
| (Source) | | 1 21 C0 minutes | | | |
| | | 1 = 31-60 minutes | | | |
| | | 0 = After 60 minutes | | | |
| | Do you find it difficult to refrain from | 1 = Yes | FTND2_Pre | FTND2_Post1 | FTND2_Post2 |
| | smoking in places where it is forbidden e.g. | 0 = No | | | |
| | in church, at the library, in cinema, etc.? | | | | |
| | Which cigarette would you hate most to | 1 = The first one in the morning | FTND3_Pre | FTND3_Post1 | FTND3_Post2 |
| | give up? | 0 = All others | | | |
| Page Break | | | | | |
| Nicotine | How many cigarettes per day do you | 0 = 10 or less | FTND4_Pre | FTND4_Post1 | FTND4_Post2 |
| Dependence ⁷ | smoke? | 1 = 11-20 | | | |
| | | 2 = 21-30 | | | |
| | | 3 = 31 or more | | | |
| | Do you smoke more frequently during the | 1 = Yes | FTND5_Pre | FTND5_Post1 | FTND5_Post2 |
| | first hours after waking than during the rest | 0 = No | | | |
| | of the day? | | | | |
| | Do you smoke if you are so ill that you are | 1 = Yes | FTND6_Pre | FTND6_Post1 | FTND6_Post2 |
| | in bed most of the day? | 0 = No | | | |
| Page Break | l | | | | |
| Previous Quit | How many times during the past 12 months | Dropdown (0-365) | PQA_Pre | | |
| Attempts ⁸ | have you stopped smoking for 1 day or | | | | |
| | longer because you were trying to quit | | | | |
| | smoking? | | | | |
| Quit | Since you started this study, how many | | | QuitAtt_Post1 | QuitAtt_Post2 |
| Attempts ⁸ | times have you stopped smoking for 1 day | | | Dropdown 0-16 | Dropdown 0-32 |
| · | or longer because you were trying to quit | | | • | |
| | smoking? | | | | |
| Smoking | Do you now smoke cigarettes every day, | 2=Every day | Smoke_Stat_Pre | Smoke_stat_pos | Smoke_Stat_post |
| Status ⁹ | some days or not at all? | 1=Some days | | t1 | 2 |
| | | 0=Not at all | | | |
| Page Break | | | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|---------------------------|---|---------------------------------|------------------|-----------------|-----------------|
| (Source) | | | | | |
| Quit Line | Do you know what national phone number | 1 = Yes | | QLAware1 | |
| Awareness | you can call for help to quit smoking? | 0 = No | | | |
| | | (If no, skip the next question) | | | |
| Page Break | | | | | |
| Quit Line | What is the national phone number? | Text Box | | QLAware2 | |
| Awareness | | | | | |
| follow up | | | | | |
| Page Break | | | | | |
| Quitline Use | Since you started this study, have you | 1 = Yes | | QL_Use_Post1 | QL_Use_Post2 |
| | called the Quitline (national phone number | 0 = No | | | |
| | for help to quit smoking)? | | | | |
| Page Break | | | | | |
| Quit | How interested are you in quitting smoking | 4=Very interested | QI1 Pre | QI1 Post1 | QI1 Post2 |
| Intention ^{4,10} | in the next month? | 3=Somewhat interested | | | Q.1 0002 |
| intention | | 2=A little interested | | | |
| | | | | | |
| | | 1=Not at all interested | | | |
| | How much do you plan to quit smoking in | 4=Very much | QI2_Pre | QI2_Post1 | QI2_Post2 |
| | the next month? | 3=Somewhat | | | |
| | | 2=A little | | | |
| | | 1=Not at all | | | |
| | How likely are you to quit smoking in the | 4=Very likely | QI3_Pre | QI3_Post1 | QI3_Post2 |
| | next month? | 3=Somewhat likely | | | |
| | | 2=A little likely | | | |
| PAGE BREAK | | 1=Not at all likely | | | |
| Quitline | If you were to quit smoking in the next | | QLI_Pre | QLI_Post1 | QLI_Post2 |
| Intention | month, how likely are you to call the | | | | |
| | national quitline for help? | | | | |
| Littering | How likely are you to dispose of your | | LI_Pre | LI_Post1 | LI_Post2 |
| Intention ⁴ | cigarette butts by dropping them on the ground in the next month? | | | | |
| Page Break | | | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|---------------------------|---|--|------------------|-----------------|-----------------|
| (Source) | | | | | |
| Self | If you decided to give up smoking | 5=Extremely | SE_Pre | SE_Post1 | SE_Post2 |
| Efficacy ^{11–13} | completely in the next month, how sure are | 4=Very much | | | |
| Deeree | you that you would succeed? | 3=Moderately | DE Due | DE Deet4 | |
| Response | How much do you think you would benefit | 2=A little 1=Not at all | RE_Pre | RE_Post1 | RE_Post2 |
| Efficacy ¹¹ | from health and other gains if you were to quit smoking permanently in the next | | | | |
| | month? | | | | |
| PAGE BREAK | | | | | |
| Positive | During the past 24 hours, how often did | 5=All of the time | Freq_Pos_Pre | Freq_Pos_Post1 | Freq_Pos_Post2 |
| Thoughts ^{14,15} | positive thoughts about smoking come to | 4=Often | | | |
| | mind (thoughts that just popped into your | 3=Sometimes | | | |
| | head, or you caught yourself thinking)? | 2=Rarely | | | |
| | | 1=Never | | | |
| PAGE BREAK | | | | | |
| Positive | [displayed if freq_pos ne never] | 1=Not at all Positive | Degree_Pos_Pre | Degree_Pos_Po | Degree_Pos_Post |
| Thoughts ^{14,15} | | 2=Slightly Positive | | st1 | 2 |
| | Considering only your positive thoughts | 3=Moderately Positive 4=Very Positive | | | |
| | about smoking during the past 24 hours, | 5=Extremely Positive | | | |
| | how positive were these thoughts? | 5 Extremely Positive | | | |
| PAGE BREAK | | | | | |
| Negative | During the past 24 hours, how often did | 5=All of the time | Freq_Neg_Pre | Freq_Neg_Post1 | Freq_Neg_Post2 |
| Thoughts ^{14,15} | negative thoughts about smoking come to | 4=Often | | | |
| | mind (thoughts that just popped into your | 3=Sometimes | | | |
| | head, or you caught yourself thinking)? | 2=Rarely 1=Never | | | |
| PAGE BREAK | | T-146461 | | | |
| Negative | [displayed if freq_neg ne never] | 1=Not at all Negative | Degree_Neg_Pre | Degree_Neg_Po | Degree_Neg_Pos |
| Thoughts ^{14,15} | [approved in neg_neg ne never] | 2=Slightly Negative | Degree_Neg_ITE | st1 | t2 |
| inougints | Considering only your negative thoughts | 3=Moderately Negative | | JLI | |
| | about smoking during the past 24 hours, | 4=Very Negative | | | |
| | how negative were these thoughts? | 5=Extremely Negative | | | |
| Page Break | ווסש וופצמנועב שבוב נוופצב נווטטצוונגי | | | | |
| rage Dieak | | | | | |

| Construct | Question Text | Re | sponse Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|--------------------------|--|-----|-------------------------------|------------------|-----------------|---------------------|
| (Source) | | | | | | |
| Current OTP | In the past 30 days, which of the following | 1. | Cigars, cigarillos, or little | OTPUse_Pre1, | | |
| Use ¹⁶ | products have you used at least once? (Pick | | cigars | OTPUse_Pre2, | | |
| | all that apply) | 2. | Smokeless tobacco, for | OTPUse_Pre3, | | |
| | | | example chewing tobacco, | OTPUse_Pre4, | | |
| | | | snuff, dip, or snus | OTPUse_Pre5, | | |
| | | | | OTPUse_Pre6, | | |
| | | 3. | Electronic cigarettes, e- | OTPUse_Pre7 | | |
| | | | cigarettes, or other vaping | | | |
| | | | devices | | | |
| | | 4. | Water pipes or Hookah | | | |
| | | 5. | Clove cigarettes | | | |
| | | 6. | Roll your own cigarettes | | | |
| | | 7. | None of the above [exclusive] | | | |
| OTP Use 2 ¹⁶ | Since you started this research study, which | 1. | Cigars, cigarillos, or little | | OTPUse_Post1_ | OTPUse_Post2_1 |
| | of the following products have you used at | | cigars | | 1, | |
| | least once? (Pick all that apply) | 2. | Smokeless tobacco, for | | OTPUse_Post1_ | OTPUse_Post2_2 |
| | | | example chewing tobacco, | | 2, | , |
| | | | snuff, dip, or snus | | OTPUse_Post1_ | OTPUse_Post2_3 |
| | | 3. | Electronic cigarettes, e- | | 3, | |
| | | | cigarettes, or other vaping | | OTPUse_Post1_ | OTPUse_Post2_4 |
| | | | devices | | 4, – – | |
| | | 4. | Water pipes or Hookah | | OTPUse_Post1_ | OTPUse_Post2_5 |
| | | 5. | Clove cigarettes | | 5, | |
| | | 6. | Roll your own cigarettes | | OTPUse_Post1_ | OTPUse_Post2_6 |
| | | 7. | None of the above [exclusive] | | 6, | |
| | | | | | OTPUse Post1 | , OTPUse_Post2_7 |
| | | | | | 7 | |
| Page Break | | | | | | |
| Knowledge ^{17,} | Does cigarette smoke contain | 1 = | = Yes | K_Inst1_Pre | K_Inst1_Post1 | K_Inst1_Post2 |
| 18 | (Matrix Question) | 0 = | = No | | | |
| | | 2 = | Don't know | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|---|---|-----------------------------|------------------|-----------------|-----------------|
| (Source) | | | | | |
| | Arsenic | | K_As_Pre | K_As_Post1 | K_As_Post2 |
| | Ammonia | | K_Am_Pre | K_Am_Post1 | K_Am_Post2 |
| | Formaldehyde | | K_Form_Pre | K_Form_Post1 | K_Form_Post2 |
| | Lead | | K_Pb_Pre | K_Pb_Post1 | K_Pb_Post2 |
| | Uranium | | K_U_Pre | K_U_Post1 | K_U_Post2 |
| Page Break | | | | | |
| Knowledge ^{17,} ¹⁸ | Does cigarette smoke cause | 1 = Yes | K_Inst2_Pre | K_Inst2_Post1 | K_Inst2_Post2 |
| | (Matrix Question) | 0 = No | | | |
| | | 2 = Don't know | | | |
| | Brain Disorders | | K_BD_Pre | K_BD_Post1 | K_BD_Post2 |
| | Breathing Problems | | K_BP_Pre | K_BP_Post1 | K_BP_Post2 |
| | Cancer | | K_Cancer_Pre | K_Cancer_Post1 | K_Cancer_Post2 |
| | Heart Damage | | K_HD_Pre | K_HD_Post1 | K_HD_Post2 |
| | Kidney Damage | | K_KD_Pre | K_KD_Post1 | K_KD_Post2 |
| | Lung Tumors | | K_LT_Pre | K_LT_Post1 | K_LT_Post2 |
| | Throat Cancer | | K_TC_Pre | K_TC_Post1 | K_TC_Post2 |
| Page Break | • | • | | | |
| Tripartite Risk ¹⁹ | If you continue smoking, how likely is it that you | (question in matrix format) | TR1 | TR1 | TR1 |
| | will get heart damage at some point in the future? | 4=Very Likely | TR1_a_Pre | TR1_a_Post1 | TR1_a_Post2 |
| | will get throat cancer at some point in the future? | 3=Likely 2=Unlikely | TR1_b_Pre | TR1_b_Post1 | TR1_b_Post2 |
| | will get lung tumors at some point in the future? | 1=Very Unlikely | TR1_c_Pre | TR1_c_Post1 | TR1_c_Post2 |
| | will get kidney damage at some point in the future? | | TR1_d_Pre | TR1_d_Post1 | TR1_d_Post2 |
| | will get breathing problems at some point in the future? | | TR1_e_Pre | TR1_e_Post1 | TR1_e_Post2 |
| | will get cancer at some point in the future? | 1 | TR1_f_Pre | TR1_f_Post1 | TR1_f_Post2 |

| Construct (Source) | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|---------------------------------------|---|-----------------------------|------------------|-----------------|-----------------|
| | will get a brain disorder at some point in the future? | | TR1_g_Pre | TR1_g_Post1 | TR1_g_Post2 |
| Page Break | | | | | |
| Tripartite Risk ¹⁹ | If you continue smoking, how fearful are you | (question in matrix format) | TR2 | TR2 | TR2 |
| | of getting heart damage in the future? | | TR2_a_Pre | TR2_a_Post1 | TR2_a_Post2 |
| | of getting throat cancer in the future? | 4=Very fearful | TR2_b_Pre | TR2_b_Post1 | TR2_b_Post2 |
| | of getting lung tumors in the future? | 3=Fearful | TR2_c_Pre | TR2_c_Post1 | TR2_c_Post2 |
| | of getting kidney damage in the future? | 2=A little fearful | TR2_d_Pre | TR2_d_Post1 | TR2_d_Post2 |
| | of breathing problems damage in the future? | 1=Not at all fearful | TR2_e_Pre | TR2_e_Post1 | TR2_e_Post2 |
| | of getting cancer in the future? | | TR2_f_Pre | TR2_f_Post1 | TR2_f_Post2 |
| | of getting a brain disorder in the future? | | TR2_g_Pre | TR2_g_Post1 | TR2_g_Post2 |
| Page Break | 1 | 1 | | 4 | |
| Tripartite Risk ¹⁹ | How much do you agree or disagree with the following statement: If I continue to smoke, I feel very vulnerable to | (question in matrix format) | TR3 | TR3 | TR3 |
| | heart damage | 4=Strongly Agree | TR3_a_Pre | TR3_a_Post1 | TR3_a_Post2 |
| | throat cancer | 3=Agree | TR3_b_Pre | TR3_b_Post1 | TR3_b_Post2 |
| | lung tumors | 2=Disagree | TR3_c_Pre | TR3_c_Post1 | TR3_c_Post2 |
| | kidney damage | 1=Strongly Disagree | TR3_d_Pre | TR3_d_Post1 | TR3_d_Post2 |
| | breathing problems | | TR3_e_Pre | TR3_e_Post1 | TR3_e_Post2 |
| | cancer | | TR3_f_Pre | TR3_f_Post1 | TR3_f_Post2 |
| | brain disorders | | TR3_g_Pre | TR3_g_Post1 | TR3_g_Post2 |
| Page Break | | | | | |
| FDA Information ^{3,} 6 | The Food and Drug Administration, or FDA, is the agency that ensures that food and drugs sold in this country are safe. | | | FDA_Info_Post1 | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|----------------------------|---|-----------------------------|------------------|-----------------|-----------------|
| (Source) | The FDA now regulates cigarettes and some | | | | |
| | other tobacco products. The next series of | | | | |
| | questions is about your opinions toward | | | | |
| | FDA in this role. | | | | |
| FDA | Do you trust the FDA to inform the public | 5 = Definitely yes | | Cred1_Post1 | |
| Credibility ^{3,6} | about the risks of tobacco products? | 4 = Probably yes | | Clear_rostr | |
| Cleanbillty | Is the FDA honest about the risks of | 3 = Neither yes or no | | Cred2_Post1 | |
| | tobacco products? | 2 = Probably no | | Cieuz_Posti | |
| | | 1 = Definitely no | | Crad2 Deat1 | |
| | Do you <u>believe</u> what the FDA says about | | | Cred3_Post1 | |
| | the risks of tobacco products? | - | | Crad A Daat1 | |
| | Is the FDA an <u>expert</u> on regulating tobacco | | | Cred4_Post1 | |
| | products? | 4 | | | |
| | Is the FDA <u>capable</u> of doing a good job | | | Cred5_Post1 | |
| | regulating tobacco products? | - | | | |
| | Can the FDA <u>effectively</u> regulate tobacco | | | Cred6_Post1 | |
| | products? | _ | | | |
| | Is the FDA <u>committed</u> to protecting the | | | Cred7_Post1 | |
| | public from possible risks of tobacco | | | | |
| | products? | | | | |
| | Do you believe that if the FDA knew that | | | Cred8_Post1 | |
| | <u>certain</u> tobacco products are <u>less</u> harmful | | | | |
| | than thought, they would tell the public? | | | | |
| Page Break | | | | | |
| Mental | During the past 30 days, about how often | (question in matrix format) | MH1 | MH1 | MH1 |
| Health ²⁰ | did you feel | | | | |
| | nervous? | 4=All of the time | MH1_a_Pre | MH1_a_Post1 | MH1_a_Post2 |
| | hopeless? | 3=Most of the time | MH1_b_Pre | MH1_b_Post1 | MH1_b_Post2 |
| | restless or fidgety? | 2=Some of the time | MH1_c_Pre | MH1_c_Post1 | MH1_c_Post2 |
| | so depressed that nothing could cheer you | 1=A little of the time | MH1_d_Pre | MH1_d_Post1 | MH1_d_Post2 |
| | up? | 0=None of the time | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|-------------------------|---|--|------------------|-----------------|-----------------|
| (Source) | that everything was an effort? | | MH1_e_Pre | MH1_e_Post1 | MH1_e_Post2 |
| | worthless? | | MH1_f_Pre | MH1_f_Post1 | MH1_f_Post2 |
| Page Break | | | | | WITI_I_F03t2 |
| Instruction | Please select the bubble to answer the | | | AE_Inst_Post1 | AE_Inst_Post2 |
| Instruction | | | | AE_IIISI_POSLI | AE_IIISI_POSIZ |
| | questions about the messages that you saw during the study: | | | | |
| Action | After seeing the messages, how likely are | 4=Very Likely | | AE1_Post1 | AE1_Post2 |
| expectancies | you to seek information about chemicals in | 3=Likely | | | |
| 21 | cigarettes? | 2=Unlikely | | | |
| | | 1=Very Unlikely | | | |
| | After seeing the messages, how likely are | 4=Very Likely | | AE2_Post1 | AE2_Post2 |
| | you to seek help to quit smoking? | 3=Likely | | | |
| | | 2=Unlikely | | | |
| | | 1=Very Unlikely | | | |
| Page Break | | | | | |
| Instruction | Please select the bubble to show how much | | | React | |
| | you agree or disagree with the statements | | | | |
| | below about the messages that you saw | | | | |
| | during the study: | | | | |
| Reactance ²² | The messages were trying to manipulate | 5=Strongly agree | | React_1_Post1 | |
| | me | 4=Somewhat agree | | | |
| | The messages made me feel aggravated | 3=Neither agree nor disagree | | React_2_Post1 | |
| | The health effects on the messages were overblown | 2=Somewhat disagree 1=Strongly disagree | | React_3_Post1 | |
| Page Break | | | | | |
| Conversation | During the study, did you talk to others | 1=yes | | Convo1_Post1 | |
| s ^{23,24} | about the messages you received about | 0=no | | | |
| 5 | cigarettes? | | | | |

| Construct (Source) | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|-----------------------------------|---|--|--|-----------------|-----------------|
| Page Break | | | | | |
| Conversation s ²⁴ | [only display if convo1_Post1 = 1] When you talked about the messages, would you say your conversations were mostly | 1=Negative about smoking cigarettes 2=Neutral about smoking cigarettes 3=Positive about smoking cigarettes | | Convo2_Post1 | |
| Page Break | | | | | |
| Behavior Instructions | Please think about yesterday | | Behav_Inst | Behav_Inst | Behav_Inst |
| | What time did you wake up yesterday? | Time | Time#1_Wake_Hou | ır | I |
| | What time did you go to sleep last night? | Time | Time#1_Sleep_Hour Time#2_Wake_Min Time#2_Sleep_Min Time#3_Wake_AMPM | | |
| Behavior ⁴ | How many times yesterday did you dispose | Dropdown list 0-100, | Time#3_Sleep_AMI | Lit1 | Lit1 |
| Dellavioi | of your cigarette butts by dropping them on the ground? | 101=refused | | | |
| | How many times yesterday did you dispose of your cigarette butts by throwing them or dropping them out of the car window? | | Lit2 | Lit2 | Lit2 |
| | How many times yesterday did you stop yourself from having a cigarette because you wanted to smoke less? | | Forgo | Forgo | Forgo |
| | How many times yesterday did you butt out a cigarette before you finished because you wanted to smoke less? | | Butt | Butt | Butt |
| PAGE BREAK | | | | | |
| Cigarettes Smoked ⁷ | Yesterday, from the time you woke up until noon, how many cigarettes did you smoke? | Dropdown list 0-100, 101=refused | Cigs_Morn | Cigs_Morn | Cigs_Morn |

| Construct (Source) | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|---|--|---|------------------|-----------------|-----------------|
| | Yesterday, from noon until you went to | | Cigs_Afternoon | Cigs_Afternoon | Cigs_Afternoon |
| | sleep, how many cigarettes did you smoke? | | | | |
| PAGE BREAK | | | | | |
| Thinking Instructions ⁴ | Overall yesterday, how much did you | | Think | Think | Think |
| Thinking About Chemicals ⁴ | Think about the chemicals in the smoke from your cigarettes? | 5=All of the time 4=Often 3=Sometimes | Think_Chem | Think_Chem | Think_Chem |
| Thinking About Risks | Think about the harm your smoking might be doing to you? | 2=Rarely 1=Never | Think_Risk | Think_Risk | Think_Risk |
| Thinking About Littering | Think about discarding cigarette butts properly? | | Think_Lit | Think_Lit | Think_Lit |
| Thinking about quitting | Think about quitting smoking? | | Think_Quit | Think_Quit | Think_Quit |
| PAGE BREAK | | | | | |
| StudyInfo1 | The next few pages give you some more information for what to expect during the study. | | StudyInfo1 | | |
| PAGE BREAK | | | PAGE BREAK | | |
| StudyInfo2 | Starting tomorrow, you will receive an email at 7am every morning for 15 days from 'admin@SurveySignal.com', with a link to a short survey. You have until 11am to open the link and answer the survey, or you will have to wait until the next one is sent. | | StudyInfo2 | | |
| PAGE BREAK | | | PAGE BREAK | | |

| Construct (Source) | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|-----------------------|--|-----------------|------------------|-----------------|-----------------|
| StudyInfo4 | After 15 days (16 days from now), you will receive another email at 7am with a link to a 20-minute survey. You will have 24 hours to open the link and answer the survey. Finally, you will receive another email 32 days from now with a link to a 20-minute | | StudyInfo4 | | |
| | survey. You will have 24 hours to open the link and answer the survey. | | | | |
| PAGE BREAK | | | PAGE BREAK | | |
| StudyInfo5 | You will be paid for the study based on how many surveys you complete with a check that will arrive in the mail after you complete the study. | | StudyInfo5 | | |
| | You will receive \$20 for completing this survey. | | | | |
| | For the daily morning surveys, you will be paid \$4 for each survey that you complete. | | | | |
| | For the 20-minute surveys at the end of the study, you will receive \$20 each if you complete them. | | | | |
| | When data collection for the full study is complete, we will have a drawing for three Amazon gift cards, with a \$200 value. Entries into the drawing will be based on completion of the morning surveys. | | | | |
| | Bonus system for Morning Survey Completion: | | | | |
| | Bronze: Total of \$10 bonus for at least 9 morning surveys. 1 entry into Amazon gift card drawing. | | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|------------|--|-----------------|------------------|-----------------|-----------------|
| (Source) | | | | | |
| | • Silver: Total of \$20 bonus for at least for | | | | |
| | at least 12 morning surveys. 2 entries | | | | |
| | into Amazon gift card drawing. | | | | |
| | • Gold: Total of \$30 bonus for completing | | | | |
| | all 15 morning surveys. 3 entries into | | | | |
| | Amazon gift card drawing. | | | | |
| | If you complete all the surveys for this | | | | |
| | study, your check amount will be \$150. | | | | |
| PAGE BREAK | | | | | |
| Quality | When you took the surveys, ere you able to | 0=No | | QA1 | |
| Assurance | see each message? | 1=Yes | | | |
| PAGE BREAK | | | | | |
| Quality | [IF QA1 = No] Why weren't you able to see | [text box] | | QA1 _comment | |
| Assurance | each message, when you took the surveys? | | | | |
| PAGE BREAK | | | | | |
| Quality | Were you able to read the text on each of | 0=No | | QA2 | |
| Assurance | the messages? | 1=Yes | | | |
| PAGE BREAK | | | | | |
| Quality | [IF QA2 = No] Why weren't you able to read | [text box] | | QA2_comment | |
| Assurance | the text on each of the messages? | | | | |
| PAGE BREAK | | | | | |
| Quality | Did you understand all of the questions? | 0=No | | QA3 | |
| Assurance | | 1=Yes | | | |
| PAGE BREAK | | | | | |
| Quality | [IF QA3 = No] Which questions did you | [text box] | | QA3_comment | |
| Assurance | have trouble understanding and why? | | | | |
| PAGE BREAK | | | | | |
| Quality | Would you do this study again? | 0=No | | QA4 | |
| Assurance | | 1=Yes | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|------------------|--|-----------------|-------------------|-----------------|-----------------|
| (Source) | | | | | |
| Quality | Would you recommend this study to a | 0=No | | QA5 | |
| Assurance | friend? | 1=Yes | | | |
| Quality | Did anything annoy you, if so, what? | [text box] | | QA6 | |
| Assurance | | | | | |
| Quality | Is there anything that you would like to | [text box] | | QA7 | |
| Assurance | share about your experience in the study? | | | | |
| Quality | Did you have any difficulty remembering | [text box] | | QA8 | |
| Assurance | how many cigarettes you smoked? If yes, | | | | |
| | please explain. | | | | |
| Quality | Would you have preferred to receive the | 0=No | | QA9 | |
| Assurance | surveys for this study via text message? | 1=Yes | | | |
| PAGE BREAK | | | | | |
| Instructions | On the next page, you will be redirected to | | SurveySignal_Inst | | |
| for Enrolling | a new link (SurveySignal). It is very | | | | |
| in Survey | important that you fill out the information | | | | |
| Signal | on that page (including name, email | | | | |
| o.B.i.a. | address, etc.). If you do not fill out that | | | | |
| | information, you will NOT be enrolled in | | | | |
| | the study. If you have any questions, email | | | | |
| | Project3@unc.edu. | | | | |
| | Once you fill in your information, | | | | |
| | SurveySignal will send you an email to | | | | |
| | verify your email address. Please make sure | | | | |
| | that you verify your email, so that you will | | | | |
| | be enrolled in the study. | | | | |
| | | | | | |
| | Note: If you are using a Mac, you will need | | | | |
| | to open the link in Chrome or Firefox. | | | | |
| End of | Unfortunately you are no longer eligible for | | | | |
| Survey for | our study. We will send you a check for \$20 | | | | |
| , anyone that | to compensate you for your time | | | | |
| is no longer a | completing this survey, but you will not be | | | | |
| ie ne ionger u | able to complete the rest of the study. | | | | |

| Construct | Question Text | Response Option | Pretest Var Name | Post 1 Var Name | Post 2 Var Name |
|--------------|---|-----------------|------------------|-----------------|-----------------|
| (Source) | | | | | |
| smoker | | | | | |
| (smoke_stat_ | Thank you for taking the time to complete | | | | |
| pre =0) | this survey! | | | | |

Morning Questionnaire (to be answered between 7am – 11am every morning)

| Construct (Source) | Question Text | Response Option | Var Name |
|--|---|----------------------------------|---|
| Study ID | [Auto-recorded] | numerical | |
| Behavior Instructions | Please think about yesterday | | Behav_Inst |
| | What time did you wake up yesterday? | Time | Time#1_Wake_Hour |
| | What time did you go to sleep last night? | Time | Time#1_Sleep_Hour Time#2_Wake_Min Time#2_Sleep_Min Time#3_Wake_AMPM Time#3_Sleep_AMPM |
| Behavior ⁴ | How many times yesterday did you dispose of your cigarette butts by dropping them on the ground? | Dropdown list 0-100, 101=refused | Lit1 |
| | How many times yesterday did you dispose of your cigarette butts by throwing them or dropping them out of the car window? | | Lit2 |
| | How many times yesterday did you stop yourself from having a cigarette because you wanted to smoke less? | | Forgo |
| | How many times yesterday did you butt out a cigarette before you finished because you wanted to smoke less? | | Butt |
| PAGE BREAK | | | |
| Cigarettes Smoked ⁷ | Yesterday, from the time you woke up until noon, how many cigarettes did you smoke? | Dropdown list 0-100, 101=refused | Cigs_Morn |
| | Yesterday, from noon until you went to sleep, how many cigarettes did you smoke? | | Cigs_Afternoon |
| PAGE BREAK | | | |
| Thinking Instructions ⁴ | Overall yesterday, how much did you | | Think |
| Thinking About Chemicals ⁴ | Think about the chemicals in the smoke from your cigarettes? | 5=All of the time 4=Often | Think_Chem |
| Thinking About Risks | Think about the harm your smoking might be doing to you? | 3=Sometimes 2=Rarely | Think_Risk |
| Thinking About Littering | Think about discarding cigarette butts properly? | 1=Never | Think_Lit |
| Thinking about quitting | Think about quitting smoking? | | Think_Quit |

| Construct (Source) | Question Text | Response Option | Var Name |
|---------------------------|--|--|-------------|
| PAGE BREAK | | | |
| Instruction | Please view the message on the next screen. After 10 seconds, you will be able to click the '>>' to move forward to the next page. [Messages should appear at the top of the screen for all | | Morn_Inst1 |
| | subsequent questions] | | |
| Page Break | | | |
| Message | Condition 1 or 2(Arsenic, Formaldehyde, Uranium, Ammonia, Lead) Or Control Messages [This should appear on the screen for 10 seconds before participants are able to move on to questions on the next page] | | Message |
| Page Break | | | |
| Affect Instruction | How much did the message make you feel | | Affect_Inst |
| Affect ^{25–27} | Anxious? | 5=Extremely | Affect_1 |
| | Sad? | 4=Very | Affect_2 |
| | Scared? | 3=Somewhat 2=A little | Affect_3 |
| | Guilty? | 1=Not at all | Affect_4 |
| | Disgusted? | | Affect_5 |
| Page Break | | | |
| Credibility ²⁸ | Please indicate how much you think the message is | | Cred_Inst |
| | Accurate | 7 = Very accurate 1 = Not very accurate | Cred_1 |
| | Authentic | 7 = Very authentic 1 = Not very authentic | Cred_2 |
| | Believable | 7 = Very believable 1 = Not very believable | Cred_3 |
| Page Break | | | |

| Construct (Source) | Question Text | Response Option | Var Name |
|-----------------------------|--|----------------------------------|--------------|
| Instruction | Please select the bubble to show how much you agree or | | PE_Inst |
| | disagree with the statements below: | | |
| Perceived | The message makes me concerned about the health effects of | 5=Strongly agree | PE_1 |
| Effectiveness ²⁹ | smoking. | 4=Somewhat agree | |
| | The message makes smoking seem unpleasant to me. | 3=Neither agree nor disagree | PE_2 |
| | The message discourages me from wanting to smoke. | 2=Somewhat disagree | PE_3 |
| | | 1=Strongly disagree | |
| | | | |
| | | | |
| PAGE BREAK | | | |
| | How many cigarettes do you think you will smoke today? | Dropdown list 0-100, 101=refused | Cigs_Predict |
| PAGE BREAK | | | |
| End of Survey | You're on day X of the 15 days of morning surveys. You've | | |
| | completed X morning survey(s) so far. We appreciate your | | |
| | response(s). Thank you! | | |

References for Measures

- 1. The GenIUSS Group. *Best Practices for Asking Questions to Idenfity Transgender and Other Gender Minority Respondents on Population-Based Surveys.*; 2014. https://williamsinstitute.law.ucla.edu/wp-content/uploads/geniuss-report-sep-2014.pdf. Accessed June 22, 2018.
- 2. Sexual Minority Assessment Research Team (SMART). *Best Practices for Asking Questions about Sexual Orientation on Surveys.*; 2009. https://williamsinstitute.law.ucla.edu/wp-content/uploads/SMART-FINAL-Nov-2009.pdf. Accessed June 22, 2018.
- 3. Boynton MH, Agans RP, Bowling JM, et al. Understanding how perceptions of tobacco constituents and the FDA relate to effective and credible tobacco risk messaging: A national phone survey of U.S. adults, 2014–2015. *BMC Public Health*. 2016;16(1):516. doi:10.1186/s12889-016-3151-5
- 4. Brewer NT, Jeong M, Mendel JR, et al. Cigarette pack messages about toxic chemicals: a randomised clinical trial. *Tob Control*. April 2018:tobaccocontrol-2017-054112. doi:10.1136/tobaccocontrol-2017-054112
- 5. Department of Health and Human Services. 2017 Annual Update of the HHS Poverty Guidelines. Vol 82.; 2017. https://www.gpo.gov/fdsys/pkg/FR-2017-01-31/pdf/2017-02076.pdf. Accessed June 22, 2018.
- 6. Schmidt AM, Jarman KL, Ranney LM, et al. Public Knowledge and Credibility Perceptions of the FDA as a Tobacco Regulator. *Nicotine Tob Res*. September 2017. doi:10.1093/ntr/ntx215
- 7. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addict*. 1991;86(9):1119-1127. http://www.ncbi.nlm.nih.gov/pubmed/1932883. Accessed February 25, 2018.
- 8. Fagan P, Augustson E, Backinger CL, et al. Quit attempts and intention to quit cigarette smoking among young adults in the United States. *Am J Public Health*. 2007;97(8):1412-1420. doi:10.2105/AJPH.2006.103697
- 9. Centers for Disease Control and Prevention. 2016 Behavioral Risk Factor Surveillance System Questionnaire.; 2016.
- 10. Klein WMP, Zajac LE, Monin MM. Worry as a Moderator of the Association Between Risk Perceptions and Quitting Intentions in Young Adult and Adult Smokers. *Ann Behav Med*. 2009;38(3):256-261. doi:10.1007/s12160-009-9143-2
- 11. Thrasher JF, Swayampakala K, Borland R, et al. Influences of Self-Efficacy, Response Efficacy, and Reactance on Responses to Cigarette Health Warnings: A Longitudinal Study of Adult Smokers in Australia and Canada. *Health Commun*. 2016;31(12):1517-1526. doi:10.1080/10410236.2015.1089456
- 12. Thrasher JF, Swayampakala K, Cummings KM, et al. Cigarette package inserts can promote efficacy beliefs and sustained smoking cessation attempts: A longitudinal assessment of an innovative policy in Canada. *Prev Med (Baltim)*. 2016;88:59-65. doi:10.1016/j.ypmed.2016.03.006
- 13. IARC HANDBOOKS OF CANCER PREVENTION. *Int Agency Res Cancer World Heal Organ*. 12. http://www.iarc.fr/en/publications/pdfsonline/prev/handbook12/Tobacco_vol12_cover.pdf. Accessed June 21, 2018.
- 14. Rice EL, Fredrickson BL. Do positive spontaneous thoughts function as incentive salience? *Emotion*. 2017;17(5):840-855. doi:10.1037/emo0000284
- 15. Orbell S, Hagger M. Temporal framing and the decision to take part in type 2 diabetes screening: Effects of individual differences in consideration of future consequences on persuasion. *Heal Psychol*. 2006;25(4):537-548. doi:10.1037/0278-6133.25.4.537
- 16. Regan AK, Promoff G, Dube SR, Arrazola R. Electronic nicotine delivery systems: adult use and awareness of the "e-cigarette" in the USA. *Tob Control*. 2013;22(1):19-23. doi:10.1136/tobaccocontrol-2011-050044

- 17. Lazard AJ, Byron MJ, Vu H, Peters E, Schmidt A, Brewer NT. Website Designs for Communicating About Chemicals in Cigarette Smoke. *Health Commun.* 2019;34(3):333-342. doi:10.1080/10410236.2017.1407276
- 18. Rohde JA, Noar SM, Horvitz C, Lazard AJ, Ross JC, Sutfin EL. The role of knowledge and risk beliefs in adolescent E-cigarette use: A pilot study. *Int J Environ Res Public Health*. 2018;15(4). doi:10.3390/ijerph15040830
- 19. Ferrer RA, Klein WMP, Persoskie A, Avishai-Yitshak A, Sheeran P. The tripartite model of risk perception (TRIRISK): distinguishing deliberative, affective, and experiential components of perceived risk. *Ann Behav Med*. 2016;50(5):653-663. doi:10.1007/s12160-016-9790-z
- 20. Kessler RC, Barker PR, Colpe LJ, et al. Screening for serious mental illness in the general population. *Arch Gen Psychiatry*. 2003;60(2):184-189. doi:10.1001/archpsyc.60.2.184
- 21. Osman A, Kowitt SD, Sheeran P, Jarman KL, Ranney LM, Goldstein AO. Information to Improve Public Perceptions of the Food and Drug Administration (FDA's) Tobacco Regulatory Role. *Int J Environ Res Public Health*. 2018;15(4). doi:10.3390/ijerph15040753
- 22. Hall MG, Sheeran P, Noar SM, et al. Negative affect, message reactance and perceived risk: how do pictorial cigarette pack warnings change quit intentions? *Tob Control*. December 2017:tobaccocontrol-2017-053972. doi:10.1136/tobaccocontrol-2017-053972
- 23. Morgan JC, Southwell BG, Noar SM, Ribisl KM, Golden SD, Brewer NT. Frequency and Content of Conversations About Pictorial Warnings on Cigarette Packs. *Nicotine Tob Res*. 2018;20(7):882-887. https://pubmed.ncbi.nlm.nih.gov/29059415/. Accessed July 13, 2020.
- 24. Noar SM, Rohde JA, Horvitz C, Lazard AJ, Cornacchione Ross J, Sutfin EL. Adolescents' receptivity to E-cigarette harms messages delivered using text messaging. *Addict Behav*. June 2018. doi:10.1016/j.addbeh.2018.05.025
- 25. Nonnemaker J, Farrelly M, Kamyab K, Busey A, Mann N. *Experimental Study of Graphic Cigarette Warning Labels: Final Results Report.*; 2010. http://www.tobaccolabels.ca/wp/wp-content/uploads/2013/12/USA-2010-Experimental-Study-of-Graphic-Cigarette-Warning-Labels-Final-Results-Report-FDA.pdf. Accessed July 11, 2018.
- 26. Keller PA, Block LG. Increasing the persuasiveness of fear appeals: The effect of arousal and elaboration. *J Consum Res.* 1996;22(4):448-459. doi:10.1086/209461
- 27. Watson D, Clark L, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales PubMed. *J Pers Soc Psychol*. 1988;54(6):1063-1070. https://pubmed.ncbi.nlm.nih.gov/3397865/. Accessed August 7, 2020.
- 28. Appelman A, Sundar SS. Measuring Message Credibility. Journal Mass Commun Q. 2016;93(1):59-79. doi:10.1177/1077699015606057
- 29. Baig SA, Noar SM, Gottfredson NC, Boynton MH, Ribisl KM, Brewer NT. UNC Perceived Message Effectiveness: Validation of a Brief Scale. *Manuscr Submitt Publ*. 2018.

Appendix B: Trial Consent Form

University of North Carolina at Chapel Hill Consent to Participate in a Research Study Adult Participants

Consent Form Version Date: V6, December 18, 2017 IRB Study # 17-0610 Title of Study: Enhancing Source Credibility in Tobacco Regulatory Communications - Aim 3 RCT Principal Investigator: Adam Goldstein Principal Investigator Department: Family Medicine Principal Investigator Phone number: (919) 966-4090 Principal Investigator Email Address: aog@med.unc.edu Co-Investigators: Leah Ranney, Seth Noar, Paschal Sheeran Funding Source and/or Sponsor: National Institutes of Health (NIH) Study Coordinator Contact: Kristen Jarman Study Contact Telephone Number: (919) 966-3016 Study Contact Email: project3@unc.edu

What are some general things you should know about research studies?

You are being asked to take part in a research study. To join the study is voluntary. You may choose not to participate, or you may withdraw your consent to be in the study, for any reason, without penalty.

Research studies are designed to obtain new knowledge. This new information may help people in the future. You may not receive any direct benefit from being in the research study. There also may be risks to being in research studies.

Details about this study are discussed below. It is important that you understand this information so that you can make an informed choice about being in this research study.

You will be given a copy of this consent form. You should ask the researchers named above, or staff members who may assist them, any questions you have about this study at any time.

What is the purpose of this study?

The purpose of this research study is to learn how people respond to messages about cigarette use. We will be asking participants to complete several surveys over 33 days, to get unique data about how people respond to messages about cigarettes.

Who should take part in the study?

Only participants that have been asked to enroll in the study are eligible. If you did not receive an email invitation to take part in the study, and you enroll anyway, you will be removed from the study. Additionally, each person can only enroll in the study once.

How many people will take part in this study?

There will be approximately 1000 people in this research study.

How long will your part in this study last?

Your part in the study will be to answer surveys delivered to your email over 33 days.

What will happen if you take part in the study?

You will receive emails during the study period to invite you to complete surveys. The chart below describes which days you will receive surveys and how long they will be.



What are the possible benefits from being in this study?

By taking part in this study, participants may increase their knowledge of the health risks associated with tobacco use. All participants may experience personal satisfaction of knowing they have contributed to a research project aimed at understanding tobacco risk communications.

What are the possible risks or discomforts involved from being in this study?

Sometimes things happen to people in research studies that may make them feel bad. These are called "risks." Taking part in this research study may involve telling us about your opinions or behaviors that you consider to be private or that cause you embarrassment. We will take steps to keep your information safe and private.

There may be uncommon or previously unknown risks. You should report any problems to the researcher.

What if we learn about new findings or information during the study?

You will be given any new information gained during the course of the study that might affect your willingness to continue your participation.

How will information about you be protected?

Participants will not be identified in any report or publication about this study. Although every effort will be made to keep research records private, there may be times when federal or state law requires the disclosure of such records, including personal information. This is very unlikely, but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to protect the privacy of personal information. In some cases, your information in this research study could be reviewed by representatives of the University, research sponsors, or government agencies (for example, the FDA) for purposes such as quality control or safety.

What if you want to stop before your part in the study is complete?

You can withdraw from this study at any time, without penalty. The investigators also have the right to stop your participation at any time. This could be because you have had an unexpected reaction, or have failed to follow instructions, or because the entire study has been stopped.

Will you receive anything for being in this study?

You will be receiving a check for up to \$150 for taking part in this study. The amount of the check is based on the number of study surveys that you complete.

At the beginning (day 1), middle (day 17) and end (day 33) of this study there are 3 surveys that will take about 20 minutes to complete. You will be paid \$20 for each of these surveys that you complete, for up to \$60.

For 15 days (from day 2 through day 16) during this study, you will receive a survey in the morning that will last about 5 minutes each to complete, you must complete this survey between 7am and 11am. You will be paid \$4 for each morning survey, but you can only take one morning survey each day. You can also earn bonuses for completing these survey.

When data collection for the full study is complete, we will have a drawing for three additional Amazon gift cards, with a \$200 value. Entries into the drawing will be based on completion of the morning surveys.

Bonus system for Survey Completion:

- Bronze: Total of \$10 bonus for at least 9 morning surveys. 1 entry into Amazon gift card drawing.
- Silver: Total of \$20 bonus for at least 12 morning surveys. 2 entries into Amazon gift card drawing.
- Gold: Total of \$30 for completing all 15 morning surveys. 3 entries into Amazon gift card drawing.

For Example: If Amy completes 2 of the 3 surveys that take 20 minutes, and 13 morning surveys, then she would get:

- 2 x \$20 for 20 minute surveys = \$40
- 13 x \$4 for morning surveys = \$52
- Silver level for survey completion = \$20
- Amy's Check Amount = \$112

Within 4-6 weeks of completing the study, you will be mailed the check for surveys that you have completed.

If you win the drawing for the Amazon gift card, we will email you the gift card within 7 days of the drawing.

Will it cost you anything to be in this study?

If you enroll in this study, you will have costs related to completing the surveys on the internet. If you use your phone to complete the surveys, this may cost you a small amount of data from your mobile phone plan which will not be covered by the study.

Who is sponsoring this study?

This research is funded by the National Cancer Institute. This means that the research team is being paid by the sponsor for doing the study. The researchers do not, however, have a direct financial interest with the sponsor or in the final results of the study.

What if you have questions about this study?

You have the right to ask, and have answered, any questions you may have about this research. If you have questions about the study (including payments), complaints, concerns, or if a research-related injury occurs, you should contact the researchers listed on the first page of this form.

What if you have questions about your rights as a research participant?

All research on human volunteers is reviewed by a committee that works to protect your rights and welfare. If you have questions or concerns about your rights as a research subject, or if you would like to obtain information or offer input, you may contact the Institutional Review Board at 919-966-3113 or by email to IRB_subjects@unc.edu.

Participant's Agreement:

I have read the information provided above. I have asked all the questions I have at this time. I voluntarily agree to participate in this research study.

[Check Box]